RU2015115898A - Новый вирус mva и его применения - Google Patents
Новый вирус mva и его применения Download PDFInfo
- Publication number
- RU2015115898A RU2015115898A RU2015115898A RU2015115898A RU2015115898A RU 2015115898 A RU2015115898 A RU 2015115898A RU 2015115898 A RU2015115898 A RU 2015115898A RU 2015115898 A RU2015115898 A RU 2015115898A RU 2015115898 A RU2015115898 A RU 2015115898A
- Authority
- RU
- Russia
- Prior art keywords
- amino acid
- gene product
- acid sequence
- mva virus
- gene
- Prior art date
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 102
- 241001183012 Modified Vaccinia Ankara virus Species 0.000 claims abstract 40
- 108090000623 proteins and genes Proteins 0.000 claims abstract 33
- 101150096528 A9L gene Proteins 0.000 claims abstract 31
- 101150085281 A3L gene Proteins 0.000 claims abstract 30
- 238000012986 modification Methods 0.000 claims abstract 28
- 230000004048 modification Effects 0.000 claims abstract 28
- 101150049392 A34R gene Proteins 0.000 claims abstract 24
- 230000035772 mutation Effects 0.000 claims abstract 21
- 150000007523 nucleic acids Chemical group 0.000 claims abstract 19
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract 15
- 241000700605 Viruses Species 0.000 claims abstract 6
- 241000700618 Vaccinia virus Species 0.000 claims abstract 2
- 150000001413 amino acids Chemical class 0.000 claims 21
- 101100350652 Vaccinia virus (strain Western Reserve) VACWR122 gene Proteins 0.000 claims 6
- 101150115056 A31R gene Proteins 0.000 claims 5
- 102220603448 Homeobox protein SIX3_A34R_mutation Human genes 0.000 claims 5
- 101100000228 Vaccinia virus (strain Western Reserve) VACWR157 gene Proteins 0.000 claims 5
- 230000002209 hydrophobic effect Effects 0.000 claims 5
- 102220311820 rs1376867262 Human genes 0.000 claims 5
- 102220005376 rs33915947 Human genes 0.000 claims 5
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 238000006467 substitution reaction Methods 0.000 claims 4
- 238000012258 culturing Methods 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 101150048714 75 gene Proteins 0.000 claims 2
- 238000002955 isolation Methods 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000006801 homologous recombination Effects 0.000 claims 1
- 238000002744 homologous recombination Methods 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 102220179791 rs752964419 Human genes 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24061—Methods of inactivation or attenuation
- C12N2710/24064—Methods of inactivation or attenuation by serial passage
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2012/069256 WO2014048500A1 (en) | 2012-09-28 | 2012-09-28 | Novel mva virus and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2015115898A true RU2015115898A (ru) | 2016-11-20 |
Family
ID=46982581
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015115898A RU2015115898A (ru) | 2012-09-28 | 2012-09-28 | Новый вирус mva и его применения |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9732325B2 (en:Method) |
| EP (1) | EP2900810B1 (en:Method) |
| JP (1) | JP2015535687A (en:Method) |
| CN (1) | CN104812894B (en:Method) |
| AU (1) | AU2012391162A1 (en:Method) |
| BR (1) | BR112015006798A2 (en:Method) |
| CA (1) | CA2885240A1 (en:Method) |
| DK (1) | DK2900810T3 (en:Method) |
| IN (1) | IN2015DN02335A (en:Method) |
| MX (1) | MX2015003687A (en:Method) |
| RU (1) | RU2015115898A (en:Method) |
| WO (1) | WO2014048500A1 (en:Method) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3052895A1 (en) * | 2017-02-23 | 2018-08-30 | Probiogen Ag | Vaccinia virus vectors related to modified vaccinia ankara (mva) with extensive genomic symmetries |
| JP7551496B2 (ja) | 2017-10-31 | 2024-09-17 | カリヴィル イムノセラピューティクス， インコーポレイテッド | 全身送達のためのプラットフォーム腫瘍溶解性ベクター |
| CN108371715A (zh) * | 2018-01-03 | 2018-08-07 | 肖小林 | 一种病毒的靶向性防治药物 |
| CN112512569A (zh) * | 2018-05-11 | 2021-03-16 | 希望之城 | 表达多个巨细胞病毒(cmv)抗原的mva载体及其用途 |
| CN112384615A (zh) | 2018-07-04 | 2021-02-19 | 普罗拜奥根股份公司 | 用于纯化包膜病毒的方法 |
| WO2022109133A1 (en) | 2020-11-19 | 2022-05-27 | Kalivir Immunotherapeutics, Inc. | Oncolytic immunotherapy by tumor micro-environment remodeling |
| WO2023128672A1 (ko) * | 2021-12-29 | 2023-07-06 | 재단법인 아산사회복지재단 | 외피외 바이러스 생산이 증가한 신규한 백시니아 바이러스 변이주 |
| WO2023223183A1 (en) | 2022-05-16 | 2023-11-23 | Crispr Therapeutics Ag | Picornaviral vectors for gene editing |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7645456B2 (en) * | 2001-04-23 | 2010-01-12 | Sanofi Pasteur Biologics Co. | Vaccinia virus strains |
| EP2363493B1 (en) | 2003-02-20 | 2012-11-14 | The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services | Novel insertion sites in pox vectors |
-
2012
- 2012-09-28 MX MX2015003687A patent/MX2015003687A/es unknown
- 2012-09-28 RU RU2015115898A patent/RU2015115898A/ru not_active Application Discontinuation
- 2012-09-28 IN IN2335DEN2015 patent/IN2015DN02335A/en unknown
- 2012-09-28 CN CN201280077370.4A patent/CN104812894B/zh active Active
- 2012-09-28 US US14/431,814 patent/US9732325B2/en active Active
- 2012-09-28 BR BR112015006798A patent/BR112015006798A2/pt not_active IP Right Cessation
- 2012-09-28 WO PCT/EP2012/069256 patent/WO2014048500A1/en active Application Filing
- 2012-09-28 JP JP2015533460A patent/JP2015535687A/ja active Pending
- 2012-09-28 AU AU2012391162A patent/AU2012391162A1/en not_active Abandoned
- 2012-09-28 EP EP12769398.4A patent/EP2900810B1/en active Active
- 2012-09-28 DK DK12769398.4T patent/DK2900810T3/en active
- 2012-09-28 CA CA2885240A patent/CA2885240A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2900810A1 (en) | 2015-08-05 |
| EP2900810B1 (en) | 2019-02-20 |
| CA2885240A1 (en) | 2014-04-03 |
| JP2015535687A (ja) | 2015-12-17 |
| MX2015003687A (es) | 2015-06-15 |
| CN104812894A (zh) | 2015-07-29 |
| DK2900810T3 (en) | 2019-04-29 |
| BR112015006798A2 (pt) | 2017-11-21 |
| WO2014048500A1 (en) | 2014-04-03 |
| AU2012391162A1 (en) | 2015-04-09 |
| US9732325B2 (en) | 2017-08-15 |
| US20150299666A1 (en) | 2015-10-22 |
| CN104812894B (zh) | 2021-10-22 |
| IN2015DN02335A (en:Method) | 2015-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2015115898A (ru) | Новый вирус mva и его применения | |
| DK2529010T3 (en) | MUTANTS OF VACCINIAVIRUS CONTAINING THE MAIN GENOMIC DELETIONS OF VAT | |
| JP6291467B2 (ja) | 組換えウイルス発現のためのプロモーター | |
| JP2015119730A5 (en:Method) | ||
| JP2010259446A5 (en:Method) | ||
| RU2008125815A (ru) | Теломеразная обратная транскриптаза птиц | |
| RU2014129788A (ru) | Вакцины против hpv | |
| JP2013507935A5 (en:Method) | ||
| JP7062003B2 (ja) | ポックスウイルス内における導入遺伝子の安定性を向上させるための組成物及び方法 | |
| ZA202100386B (en) | Influenza virus hemagglutinin mutants | |
| JP6235697B2 (ja) | 変異ワクシニアウイルス株、その使用およびそれを作製する方法 | |
| CA2372709C (en) | Vector for integration of heterologous sequences into poxviral genomes | |
| RU2014129220A (ru) | Новый аттенуированный полиовирус: pv-1 mono-cre-x | |
| CN1723285A (zh) | 重组的mva及其产生方法 | |
| US11104884B2 (en) | Vaccinia virus vectors related to MVA with extensive genomic symmetries | |
| EP2635687B1 (en) | Modulation of immune responses by the poxviral k4 protein | |
| CN108239620A (zh) | IFN-β1编码基因缺失的MDCK细胞株及其构建方法和应用 | |
| CN104975043A (zh) | 构建重组mva病毒的带有标记基因自删除系统的穿梭载体 | |
| KR101677231B1 (ko) | 무혈청배지（serum free medium）를 이용한 메갈로사이티바이러스의 효율적 제조방법 | |
| KR20140122603A (ko) | 세포외 피막성 백시니아 바이러스의 생성과 관련된 단백질을 코딩하는 폴리뉴클레오티드로 형질전환된 숙주세포 | |
| CN109504643B (zh) | 整合四拷贝功能性f18菌毛操纵子基因的益生菌克隆株、构建方法及应用 | |
| Kan et al. | Generation of an attenuated Tiantan vaccinia virus by deletion of the ribonucleotide reductase large subunit | |
| RU2012117014A (ru) | Способ получения рекомбинантного капсидного белка вируса гепатита е. рекомбинантная вакцина для профилактики вирусного гепатита е. | |
| JP2019187249A (ja) | 増殖性ヘルパーワクシニアウイルスを使用するポックスウイルスの製造方法 | |
| RU2016145253A (ru) | Химерный белок, синтетическая днк, кодирующая указанный белок, экспрессионный вектор, штамм-продуцент синтетической днк и способ получения плазмидной днк |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20150929 |